Dror Bashan
CIK: 0001781450
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Protalix BioTherapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
320K shares- - Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
Award(A)DirectRestricted Stock Units
160K shares- - Dec 19, 2025PLX
Protalix BioTherapeutics, Inc.
Purchase(P)Direct56K shares at avg. $1.81$101K - Sep 3, 2025PLX
Protalix BioTherapeutics, Inc.
Award(A)Indirect195K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 320,000 | - | - | Direct |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award(A) Restricted Stock Units | 160,000 | - | - | Direct |
| Dec 19, 2025 | PLX Protalix BioTherapeutics, Inc. | Purchase(P) | 56,000 | $1.81 | $101,360 | Direct |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | Award(A) | 195,000 | - | - | Indirect |
1-4 of 4 transactions
About Bashan Dror
Bashan Dror (SEC CIK 0001781450) files insider reports with the SEC as PRESIDENT AND CEO of Protalix BioTherapeutics, Inc. (PLX).
Signal8 holds 3 ownership filings by Bashan Dror, all Form 4s, filed between Sep 4, 2025 and Sep 4, 2026. Those filings report 4 transactions, from Sep 3, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bashan Dror's filings is in CARMIEL.
Recent filings by Bashan Dror
Other insiders filing for Protalix BioTherapeutics, Inc. (PLX)
- Schwartz Aharon, Director
- Naos Yaron, Sr. VP & COO
- Melincoff Gwen A, Director
- Elze Christian, Director
- Boudes Pol F, Director
- Bar-Shalev Amos, Director